Leveraging its proprietary AI-powered drug design platform TransProtein, TransProtein has successfully designed a GLP-1 receptor agonist (GLP-1 RA) with a longer half-life and superior efficacy. The half-life (T1/2) of this new-generation GLP-1 RA is three times that of semaglutide, achieving long-acting weight-loss medication. This is also the world's first AI-designed blockbuster weight-loss drug.

Intelligent Medicine Original has designed over tens of thousands of novel GLP-1 RA peptide sequences using proprietary algorithms. Following a self-developed, highly efficient screening process, three candidate peptide drugs were successfully selected, and animal efficacy and pharmacokinetic experiments were conducted.

AI-powered drug design and screening based on TransProtein shortens the drug design cycle and significantly improves the success rate of drug design. The above experimental results are from a single round of experiments, further validating the technological advantages of Intelligent Medicine Original in the field of protein drug design. Its proprietary protein design method can also be widely applied to the development of other protein drugs, providing strong support for innovative drug research and development.